STOCK TITAN

Arteris (AIP) VP and General Counsel sells 6,500 shares, exercises 6,500 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arteris, Inc. VP and General Counsel Paul L. Alpern reported multiple transactions in the company’s common stock on July 1, 2026. He sold a total of 6,500 shares in open-market transactions at weighted average prices ranging from about $43.70 to $47.50, carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026. On the same date, he exercised stock options to acquire 6,500 shares of common stock at exercise prices of $9.28 and $0.56 per share. Following these transactions, he continues to hold more than 80,000 shares of Arteris common stock directly.

Positive

  • None.

Negative

  • None.
Insider Alpern Paul L
Role VP and General Counsel
Sold 6,500 shs ($296K)
Type Security Shares Price Value
Exercise Incentive Stock Option (right to buy) 4,000 $0.00 --
Exercise Non-Qualified Stock Option (right to buy) 2,500 $0.00 --
Exercise Common Stock 4,000 $0.56 $2K
Exercise Common Stock 2,500 $9.28 $23K
Sale Common Stock 2,096 $44.0182 $92K
Sale Common Stock 983 $45.0793 $44K
Sale Common Stock 2,521 $46.2265 $117K
Sale Common Stock 900 $47.1131 $42K
Holdings After Transaction: Incentive Stock Option (right to buy) — 57,000 shares (Direct, null); Non-Qualified Stock Option (right to buy) — 25,000 shares (Direct, null); Common Stock — 84,384 shares (Direct, null)
Footnotes (1)
  1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on February 23, 2026. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.70 to $44.69 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.81 to $45.79 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.815 to $46.51 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.85 to $47.50 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Incentive stock option, 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26, 2020. Non-qualified stock options, vesting in 16 equal quarterly installments of 1/16th each, beginning on April 1, 2025.
Shares sold 6,500 shares Total Arteris common stock sold on July 1, 2026
Shares from option exercises 6,500 shares Common shares acquired through option exercises on July 1, 2026
Sale price range $43.70–$47.50 per share Weighted average sale prices across multiple transactions
Incentive option strike price $0.56 per share Exercise price for 4,000 incentive stock option shares
Non-qualified option strike price $9.28 per share Exercise price for 2,500 non-qualified stock option shares
Shares held after transactions Over 80,000 shares Direct Arteris common stock holdings following reported trades
10b5-1 plan adoption date February 23, 2026 Date Alpern adopted the trading plan used for these sales
Rule 10b5-1 trading plan regulatory
"Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported in Column 4 is a weighted average sale price."
Incentive stock option financial
"Incentive stock option, 25% of the total shares vested on August 26, 2020"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
Non-qualified stock options financial
"Non-qualified stock options, vesting in 16 equal quarterly installments"
Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Alpern Paul L

(Last)(First)(Middle)
C/O ARTERIS, INC.
900 E. HAMILTON AVE., SUITE 300

(Street)
CAMPBELL CALIFORNIA 95008

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
VP and General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M(1)4,000A$0.5684,384D
Common Stock07/01/2026M(1)2,500A$9.2886,884D
Common Stock07/01/2026S(1)2,096D$44.0182(2)84,788D
Common Stock07/01/2026S(1)983D$45.0793(3)83,805D
Common Stock07/01/2026S(1)2,521D$46.2265(4)81,284D
Common Stock07/01/2026S(1)900D$47.1131(5)80,384D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Incentive Stock Option (right to buy)$0.5607/01/2026M4,000 (6)10/23/2029Common Stock4,000$0.0057,000D
Non-Qualified Stock Option (right to buy)$9.2807/01/2026M2,500 (7)02/20/2035Common Stock2,500$0.0025,000D
Explanation of Responses:
1. Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on February 23, 2026.
2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.70 to $44.69 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.81 to $45.79 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.815 to $46.51 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $46.85 to $47.50 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. Incentive stock option, 25% of the total shares vested on August 26, 2020; thereafter, 1/48th of the total shares vested monthly for 3 years, beginning on September 26, 2020.
7. Non-qualified stock options, vesting in 16 equal quarterly installments of 1/16th each, beginning on April 1, 2025.
Remarks:
/s/ Paul Alpern07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Arteris (AIP) VP and General Counsel Paul L. Alpern report?

Paul L. Alpern reported selling 6,500 shares of Arteris common stock and exercising options for 6,500 shares. The sales were open-market transactions, while the exercises converted stock options into common shares on the same date.

How many Arteris (AIP) shares did Paul L. Alpern sell and at what prices?

He sold a total of 6,500 Arteris common shares in several trades. Weighted average sale prices ranged from about $43.70 to $47.50 per share, based on multiple transactions within each stated price band.

Were Paul L. Alpern’s Arteris (AIP) stock sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026. Such pre-arranged plans automate trading and can reduce the significance of transaction timing as a signal.

What stock options did Paul L. Alpern exercise in this Arteris (AIP) Form 4?

He exercised options covering 6,500 shares of Arteris common stock. This included 2,500 non-qualified stock option shares with a $9.28 exercise price and 4,000 incentive stock option shares with a $0.56 exercise price.

How many Arteris (AIP) shares does Paul L. Alpern hold after these transactions?

After the reported sales and option exercises, he directly holds more than 80,000 shares of Arteris common stock. Individual transaction rows show post-transaction direct holdings above this level across the reported entries.

What are the key terms of Paul L. Alpern’s Arteris (AIP) stock option grants?

One incentive stock option vested 25% on August 26, 2020, with the remainder vesting monthly over three years. A non-qualified option vests in 16 equal quarterly installments beginning April 1, 2025, according to the disclosed vesting footnotes.